Search - tctmd.com

Displaying 41 - 60 of 163

Sort: Relevancy | Date

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

Presenter: Robert A. Harrington, Kurt Huber, Christopher B. Granger

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Presentation TCT 2017

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

Presenter: Robert A. Harrington, Kurt Huber, Jean-François Tanguay

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

Presentation TCT 2017

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

Presenter: Robert A. Harrington, Kurt Huber, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

News Conference News TCT 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Yael L. Maxwell

November 01, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Presenter: Davide Capodanno, Tullio Palmerini, Ioanna Kosmidou

October 31, 2017

Presentation TCT 2017

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Presenter: Christopher B. Granger, Horst Sievert, Maurice Buchbinder

October 30, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Presenter: Christopher B. Granger, Horst Sievert, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Presenter: Christopher B. Granger, Horst Sievert, Pascal Vranckx

October 30, 2017

Presentation TCT 2017

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

Presenter: Christopher B. Granger, Horst Sievert, Renu Virmani

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

News Daily News

Preventing Dementia May Be Another Reason to Take Oral Anticoagulants for A-fib

Todd Neale

October 25, 2017

Advertisement

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Origin of Thromboemboli in Atrial Fibrillation: Valvular vs Non-Valvular AF, Large vs Small Left Atria, and Other Considerations

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Preventing Dementia May Be Another Reason to Take Oral Anticoagulants for A-fib

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content